Eugene Nwankwo

Dr. Eugene Nwankwo


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2024 in Cancers
Verified
Journal Article
Open access
PDF file
ENEugene Nwankwo
Eugene Nwankwo
AGAmerti Guta
Amerti Guta
SCScarlett Cao
Scarlett Cao
JYJudong Yang
Judong Yang
AAAbubaker Abdalla
Abubaker Abdalla
LRLewis R Roberts
Lewis R Roberts
Biliary tract cancers, including cholangiocarcinoma, gallbladder, and ampulla of Vater cancers, rank second among hepatobiliary cancers, known for their poor prognoses. The United States has witnessed a notable increase in intrahepatic cholangiocarcinoma incidence. This study examines the incidence and survival outcomes of biliary tract cancers in Olmsted County, Minnesota from 1976 to 2018. Using data from the Rochester Epidemiology Project (REP), residents aged 20 and above were analyzed across four eras. Incidence rates were calculated and adjusted for age and sex, and temporal trends were assessed using Poisson regression. Intrahepatic cholangiocarcinoma exhibited a significant escalation in incidence rates over time, while gallbladder cancers showed a decline among women. Median survival times for biliary tract cancers notably improved. These findings confirm the rising incidence of intrahepatic cholangiocarcinoma and suggest improving survival rates. Nevertheless, the overall prognosis for biliary tract cancers remains very poor, emphasizing the continual need for enhanced management strategies and further research.

23 October 2026 in Journal of Clinical Gastroenterology
Verified
Journal Article
Closed access
JAJad P. AbiMansour
Jad P. AbiMansour
PJPreethi Jagannath
Preethi Jagannath
ENEugene Nwankwo
Eugene Nwankwo
SGSushil Garg
Sushil Garg
SHSamuel Han
Samuel Han
VCVinay Chandrasekhara
Vinay Chandrasekhara
Goals: Evaluate the relationship between metabolic syndrome (MetS) and clinical outcomes in individuals with necrotizing pancreatitis (NP) and infected pancreatic necrosis (IPN). Background: MetS affects a significant proportion of the global population and is associated with low-grade systemic inflammation and immune dysregulation. This has implications for several disease processes, but the impact of MetS on patients with NP is not well characterized. Study: A retrospective cohort study of patients admitted with NP at a single tertiary center was performed. MetS was defined as meeting any 3 of the following criteria: BMI ≥30 kg/m 2 , triglycerides ≥150 mg/dL, fasting glucose ≥110 mg/dL, blood pressure ≥130/85 mm Hg, and low HDL (<40 mg/dL men, <50 mg/dL women). The need for intensive care, hospital length of stay, development of organ failure, and mortality were compared in patients with NP with or without MetS. Secondary outcomes included the incidence of IPN. Results: A total of 276 (154 MetS, 55.8%) patients were identified. Individuals with MetS more frequently required ICU-level care (38.3% vs. 17.2%; P <0.001) and longer length of stay (9.0 vs. 5.0 d; P =0.029). There was a higher risk of sepsis in those with MetS (27.5% vs. 15.6%; P =0.019), as well as respiratory failure (31.2% vs. 18%; P =0.013), renal failure (35.7% vs. 21.3%; P =0.009), and in-hospital mortality (17.5% vs. 8.2%; P =0.024). The incidence of IPN was higher in patients with MetS (39.6% vs. 23.0%; P =0.003). Conclusion: The presence of MetS in individuals with NP was associated with worsened outcomes, including increased incidence of IPN, sepsis, organ failure, ICU admission, and mortality during index hospitalization.